STOCK TITAN
  1. Home
  2. Sec-filings
  3. INZY
  4. [EFFECT] Inozyme Pharma, Inc. SEC Filing

[EFFECT] Inozyme Pharma, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 1, 2025
Accession Number: 0001193125-25-153585
Submission Type: POS AM
CIK: 0001693011
Company Name: Inozyme Pharma, Inc.
File Number: 333-258702

Source: View Original Filing on SEC EDGAR

Stock INZY logo
Inozyme Pharma, Inc.

NASDAQ:INZY

INZY Rankings

#4235 Ranked by Market Cap
N/A Ranked by Dividends

INZY Latest News

Jul 1, 2025
BioMarin Announces Completion of Acquisition of Inozyme
Jun 20, 2025
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
May 16, 2025
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 14, 2025
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
Apr 10, 2025
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

INZY Latest SEC Filings

Aug 27, 2025
[SCHEDULE 13D/A] Inozyme Pharma, Inc. SEC Filing
Aug 14, 2025
[SCHEDULE 13G/A] Inozyme Pharma, Inc. SEC Filing
Aug 13, 2025
[SCHEDULE 13G/A] Inozyme Pharma, Inc. SEC Filing
Aug 12, 2025
[SCHEDULE 13G/A] Inozyme Pharma, Inc. SEC Filing
Jul 11, 2025
[15-12G] Inozyme Pharma, Inc. SEC Filing

INZY Stock Data

257.60M
63.15M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
BOSTON